Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells

European Journal of Pharmacology

Volumn 650, Issue 2-3, 2011, Pages 519-525

  Cheng, Chi Chih ^a,b   Hsueh, Chi Mei ^a   Liang, Kae Woei ^b   Ting, Chih Tai ^b   Wen, Chi Luan ^c,d   Hsu, Shih Lan ^b,c  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d FISHERIES RESEARCH INSTITUTE   (Taiwan)

Author keywords

AP 1; Berberine; C Jun; JNK; Paraoxonase 1

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARYLDIALKYLPHOSPHATASE 1; BERBERINE; CURCUMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; ATHEROSCLEROSIS; BINDING SITE; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA FLANKING REGION; DRUG MECHANISM; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ARYLDIALKYLPHOSPHATASE; BERBERINE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

EID: 78651113240     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.051     Document Type: Article

References (36)

1. K. Arii, T. Suehiro, K. Ota, Y. Ikeda, Y. Kumon, F. Osaki, M. Inoue, S. Inada, N. Ogami, H. Takata, K. Hashimoto, and Y. Terada Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells Atherosclerosis 202 2009 439 445
2. R. Ashida, K. Tominaga, E. Sasaki, T. Watanabe, Y. Fujiwara, N. Oshitani, K. Higuchi, S. Mitsuyama, H. Iwao, and T. Arakawa AP-1 and colorectal cancer Inflammopharmacology 13 2005 113 125
3. M. Aviram, and B. Fuhrman Wine flavonoids protect against LDL oxidation and atherosclerosis Ann. NY Acad. Sci. 957 2002 146 161
4. M. Aviram, M. Rosenblat, C.L. Bisgaier, R.S. Newton, S.L. Primo-Parmo, and B.N. La Du Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase J. Clin. Invest. 101 1998 1581 1590
5. M.A. Bogoyevitch, I. Boehm, A. Oakley, A.J. Ketterman, and R.K. Barr Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential Biochim. Biophys. Acta 1697 2004 89 101
6. L.G. Costa, A. Vitalone, T.B. Cole, and C.E. Furlong Modulation of paraoxonase (PON1) activity Biochem. Pharmacol. 69 2005 541 550
7. S. Deakin, I. Leviev, M. Gomaraschi, L. Calabresi, G. Franceschini, and R.W. James Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism J. Biol. Chem. 277 2002 4301 4308
8. S. Deakin, I. Leviev, M.C. Brulhart-Meynet, and R.W. James Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position -107, implicating the Sp1 transcription factor Biochem. J. 372 2003 643 649
9. M. Gong, M. Garige, R. Varatharajalu, P. Marmillot, C. Gottipatti, L.C. Leckey, and R.M. Lakshman Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation Biochem. Biophys. Res. Commun. 379 2009 1001 1004
10. C. Gouedard, R. Barouki, and Y. Morel Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism Mol. Cell. Biol. 24 2004 5209 5222
11. C. Gouedard, R. Barouki, and Y. Morel Induction of the paraoxonase-1 gene expression by resveratrol Arterioscler. Thromb. Vasc. Biol. 24 2004 2378 2383
12. Y. Ikeda, T. Suehiro, M. Inoue, Y. Nakauchi, T. Morita, K. Arii, H. Ito, Y. Kumon, and K. Hashimoto Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus Metabolism 47 1998 598 602
13. T. Itahara, T. Suehiro, Y. Ikeda, M. Inoue, T. Nakamura, Y. Kumon, M. Kawada, and K. Hashimoto Serum paraoxonase and arylesterase activities in hemodialysis patients J. Atheroscler. Thromb. 7 2000 152 158
14. R.W. James, and S.P. Deakin The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity Free Radic. Biol. Med. 37 2004 1986 1994
15. D.G. Kang, E.J. Sohn, E.K. Kwon, J.H. Han, H. Oh, and H.S. Lee Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels Vasc. Pharmacol. 39 2002 281 286
16. W. Kong, J. Wei, P. Abidi, M. Lin, S. Inaba, C. Li, Y. Wang, Z. Wang, S. Si, H. Pan, S. Wang, J. Wu, Z. Li, J. Liu, and J.D. Jiang Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins Nat. Med. 10 2004 1344 1351
17. Y. Kumon, T. Suehiro, Y. Ikeda, and K. Hashimoto Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6 Life Sci. 73 2003 2807 2815
18. J.K. Kundu, Y.K. Shin, and Y.J. Surh Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets Biochem. Pharmacol. 72 2006 1506 1515
19. C.W. Lau, X.Q. Yao, Z.Y. Chen, W.H. Ko, and Y. Huang Cardiovascular actions of berberine Cardiovasc. Drug Rev. 19 2001 234 244
20. S. Lee, H.J. Lim, J.H. Park, K.S. Lee, Y. Jang, and H.Y. Park Berberine-induced LDLR up-regulation involves JNK pathway Biochem. Biophys. Res. Commun. 362 2007 853 857
21. F. Osaki, Y. Ikeda, T. Suehiro, K. Ota, S. Tsuzura, K. Arii, Y. Kumon, and K. Hashimoto Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells Atherosclerosis 176 2004 279 287
22. S.L. Primo-Parmo, R.C. Sorenson, J. Teiber, and B.N. La Du The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family Genomics 33 1996 498 507
23. L. Rackova, M. Majekova, D. Kost'alova, and M. Stefek Antiradical and antioxidant activities of alkaloids isolated from Mahonia aquifolium. Structural aspects Bioorg. Med. Chem. 12 2004 4709 4715
24. D. Rochu, E. Chabriere, and P. Masson Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning Toxicology 233 2007 47 59
25. P.D. Sarkar, T.M.S., and B. Madhusudhan Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease Clin. Chim. Acta 373 2006 77 81
26. E. Shaulian, and M. Karin AP-1 as a regulator of cell life and death Nat. Cell Biol. 4 2002 E131 E136
27. Q. Shen, I.P. Uray, Y. Li, T.I. Krisko, T.E. Strecker, H.T. Kim, and P.H. Brown The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors Oncogene 27 2008 366 377
28. D.M. Shih, L. Gu, Y.R. Xia, M. Navab, W.F. Li, S. Hama, L.W. Castellani, C.E. Furlong, L.G. Costa, A.M. Fogelman, and A.J. Lusis Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature 394 1998 284 287
29. A. Shirwaikar, K. Rajendran, and I.S. Punitha In vitro antioxidant studies on the benzyl tetra isoquinoline alkaloid berberine Biol. Pharm. Bull. 29 2006 1906 1910
30. S. Shishodia, M.M. Chaturvedi, and B.B. Aggarwal Role of curcumin in cancer therapy Curr. Probl. Cancer 31 2007 243 305
31. S. Shishodia, G. Sethi, and B.B. Aggarwal Curcumin: getting back to the roots Ann. NY Acad. Sci. 1056 2005 206 217
32. C.J. Thirupurasundari, R. Padmini, and S.N. Devaraj Effect of berberine on the antioxidant status, ultrastructural modifications and protein bound carbohydrates in azoxymethane-induced colon cancer in rats Chem. Biol. Interact. 177 2009 190 195
33. M. Tomas, M. Senti, F. Garcia-Faria, J. Vila, A. Torrents, M. Covas, and J. Marrugat Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients Arterioscler. Thromb. Vasc. Biol. 20 2000 2113 2119
34. A. Tward, Y.R. Xia, X.P. Wang, Y.S. Shi, C. Park, L.W. Castellani, A.J. Lusis, and D.M. Shih Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice Circulation 106 2002 484 490
35. T.M. van Himbergen, L.J. van Tits, M. Roest, and A.F. Stalenhoef The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine Neth. J. Med. 64 2006 34 38
36. X.H. Zeng, X.J. Zeng, and Y.Y. Li Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am. J. Cardiol. 92 2003 173 176